Brief: Integragen presents new data for its miR-31-3p biomarker at 2016 ESMO Congress
10/10/2016 17:02
Oct 10 (Reuters) - Integragen SA ALINT.PA :
* New data on Integragen's mir-31-3p biomarker featured in presentation at 2016 ESMO
Congress
* Data presented concludes that mir-31-3p expression is predictive of anti-EGFR therapy
effect on objective response, depth of response, and early tumor shrinkage in patients with
metastatic colorectal cancer enrolled in prospective, randomized FIRE-3 Trial
Source text for Eikon: ID:nBw1rGG07a
Further company coverage: ALINT.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))